Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913176 | 1.00 | GRM5 (0.47) | GRM5HCAR2KDM4ENAPRTCDK2 | |
| SCHEMBL28194852 | 0.87 | GRM5 (0.40) | GRM5HCAR2KDM4ENAPRTCDK2 | |
| Dimethylformamide SCHEMBL27784389 | 0.86 | GRM5 (0.39) | GRM5HCAR2KDM4ENAPRTCDK2 | |
| SCHEMBL27858703 | 0.84 | GRM5 (0.49) | GRM5HCAR2KDM4ENAPRTCDK2 | |
| SCHEMBL69399 | 0.83 | KDM4E (0.55) | HCAR2KDM4ENAPRTALOX15ALDH1A1 | |
| SCHEMBL376231 | 0.82 | GRM5 (0.47) | GRM5HCAR2KDM4ENAPRTCDK2 | |
| SCHEMBL30354632 | 0.80 | GRM5 (0.46) | GRM5HCAR2KDM4ECDK2CTSA | |
| SCHEMBL12091007 | 0.80 | GRM5 (0.46) | GRM5HCAR2KDM4ECDK2CTSA | |
| SCHEMBL741061 | 0.80 | SIRT6 (0.50) | GRM5CDK2CTSAS1PR3TSHR | |
| SCHEMBL31555012 | 0.80 | SIRT6 (0.50) | GRM5CDK2CTSAS1PR3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997228-A | The preparation method and application of 6- chloropyrazine -2- amides compound containing diphenyl ether base | 陈磊 | 2018-12-14 | — | — | CN | claimed |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-4646402-A1 | GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4522612-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5516661-A | CULTIVATING AEROBIC BIOMASS OF PSEUDOMONAS, ALCALIGENES, OR ARTHROBACTER WITH NICOTINIC ACID OR SALTS; HYDROXYLATION | LONZA LTD. (CH) | 1996-05-14 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| US-5364939-A | Chlorinating hydroxy carboxylic acid with phosphorus pentachloride in phosphoroxy chloride | LONZA LTD. (CH) | 1994-11-15 | — | — | US | disclosed |
| EP-0556465-A2 | Microbiological process for the preparation of aromatic hydroxylated heterocyclic acids | LONZA AG (CH) | 1993-08-25 | — | — | EP | disclosed |
| EP-0227026-B1 | PYRAZINE DERIVATIVE, A PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREFROM | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1990-04-18 | — | — | EP | disclosed |
| US-4792547-A | Pyrazine-2-carboxamide derivatives useful in treating allergic disease | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1988-12-20 | — | — | US | disclosed |
| EP-0227026-A1 | Pyrazine derivative, a process for preparation thereof and pharmaceutical composition therefrom | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | GRM5 556/4885HCAR2 2641/4885KDM4E 3762/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | GRM5 156/4885HCAR2 41/4885KDM4E 3486/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | GRM5 2770/4885HCAR2 2605/4885KDM4E 549/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | GRM5 4439/4885HCAR2 621/4885KDM4E 1675/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | GRM5 156/4885HCAR2 41/4885KDM4E 3486/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | GRM5 156/4885HCAR2 41/4885KDM4E 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.